The Risks of Health E-Cigarettes: Safety Concerns Arise

Sep.07.2022
The Risks of Health E-Cigarettes: Safety Concerns Arise
Healthy" e-cigarettes, containing vitamins and oils, are growing in popularity but lack safety testing and may have long-term risks.

The so-called health electronic cigarettes are becoming increasingly popular. Unlike regular electronic cigarettes that contain nicotine, these products contain vitamins or essential oils. However, they have caught the attention of the US Food and Drug Administration (FDA).


Healthy electronic cigarettes, also known as 'nutritional supplement diffusers,' encompass a range of products that share a common source found in electronic cigarettes. Unlike traditional cigarettes, electronic cigarettes deliver nicotine to the lungs without combustion or tobacco. This allows for the removal of harmful ingredients such as tobacco tar. Electronic cigarettes work by utilizing energy from a battery to heat liquid, creating an inhalable vapor.


A new line of products aims to use the same inhalation delivery system for various non-nicotine products, including popular vitamins (such as B12 and C), milk thistle, melatonin (a hormone), green tea, and various essential oils. The health e-cigarette company claims that different combinations of these additives can help improve focus, promote sleep, and even aid in weight loss.


Inhaling rather than swallowing these compounds allows for quicker absorption into the bloodstream, hence theoretically making vitamins and supplements more effective when inhaled.


Many of these additives will be familiar as supplements deemed safe for ingestion. However, most lack inhalation safety testing, particularly in regards to potential long-term harm. Because healthy e-cigarettes do not contain nicotine, they have managed to evade regulatory agencies.


The onset of the 2019 outbreak of e-cigarette or vaping product use associated lung injury (or EVALI) in the United States highlighted the importance of detecting ingestion methods. In the initial report of 60 deaths related to EVALI, vitamin E acetate was identified as a key factor causing lung damage in these individuals. Vitamin E is a common food additive, therefore this clearly emphasizes that even well-known healthy substances can have serious consequences on one's health when inhaled.


These devices are quite innovative in the market, and therefore research on their safety is scarce. Administering incorrect patient groups with untested methods could render many benign or beneficial compounds harmful. For example, the benefits of vitamin C are well-known, but using high doses of vitamin C has been shown to increase the risk of death in sepsis patients.


Vitamin B12 is also a popular additive in these devices. B12 injections are highly effective in restoring vitamin levels for those who are deficient. However, there is no evidence to support any benefits for people with normal B12 levels. Additionally, we lack evidence on the safety or efficacy of inhaling B12.


A research conducted in 1967 revealed that inhaling vitamin B12 showed no benefits compared to injecting supplements. However, even at that time, researchers pointed out the potential risk of lung damage.


We can also examine information on components commonly shared with electronic cigarettes to identify potential impacts. Some products offer Vitamin B12 dissolved in vegetable glycerin, a common ingredient in e-liquids. Other products use propylene glycol or a mixture of two liquids. When heated, these components can break down into harmful chemicals known as reactive carbonyl compounds, such as formaldehyde.


These chemicals have been found to damage alveolar macrophages, which are crucial immune cells in the lungs, in a manner that does not depend on the presence of nicotine. Similar findings have been observed in other important airway and immune cells.


Electronic cigarettes that offer essential oils as a healthier option may also be subject to similar issues. They contain a mixture of compounds known as terpenes, as well as other chemicals similar to those found in e-liquids.


According to reports, terpenes have a range of benefits, including anti-cancer, anti-allergy and antibacterial properties, indicating potential benefits of taking these essential oils. However, terpenes can be degraded by heat and may be broken down into harmful compounds when inhaled, which can irritate the respiratory tract and potentially be toxic to cells at higher doses and longer exposure times.


Due to the similarities between electronic cigarettes and health e-cigarettes, these companies are now facing increasingly strict scrutiny from public health institutions. The FDA warns that health e-cigarettes are "unsafe," "ineffective," and "unproven.


Statement:


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.


Due to the limitations of the translator’s skills, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government's stance and statements on any issues related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13